Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
4831 Views
Dr KK Aggarwal 15 November 2020
A critical review recently published in the Journal of Dental Research examined evidence for various mouth rinses with regard to their potential anti-SARS-CoV-2 activity.1 The review concluded that mouthwashes with antiviral ingredients could help decrease COVID-19 transmission by reducing viral loads in the mouths of infected patients when they cough, sneeze or speak.2
Only one study was found to investigate the use of mouth rinses containing chlorhexidine against SARS-CoV-2. While chlorhexidine reduced the viral load postgargling for 2 hours, this decrease was transient and the viral load increased again.3
A prospective clinical pilot study found no significant decrease in SARS-CoV-2 intraoral viral load with 1% hydrogen peroxide mouthrinse in COVID-19 patients.4
Investigation into SARS-CoV-2 resistance of compounds in garlic essential oil showed that 17 organosulfur compounds had strong interactions with the amino acids of the ACE2 protein and the main protease (PDB6LU7) of SARS-CoV-2, thus predicting its antiviral effects. But this was an in silico study using molecular docking technique.5
Evidence for mouthrinses containing povidone-iodine (PVP-I) was also reviewed. In vitro studies have demonstrated that PVP-I also has virucidal activity against SARS-CoV-2.
According to Dr Florence Carrouel of University Claude Bernard Lyon in France, co-author of the review, everyone should be using these mouthwashes because people can be infected and may not realize it. Three doses of antiviral mouthwash should be used the day before a meeting, and one dose the morning of the event. COVID-19 patients should be using mouthwash regularly for 7-10 days.2
PVP-I has been a widely used antiseptic for many decades. It has the broadest spectrum of antimicrobial action compared with other common antiseptics such as chlorhexidine with activity against Gram‐positive and Gram‐negative bacteria, bacteria spores, fungi, protozoa and several viruses.10 The multimodal mechanisms of action, rapid onset of action, persistent effect, lack of reported resistance, and an excellent safety profile are other advantages of PVP-I over other commonly available antiseptics.
PVP-I has been demonstrated to have greater antiviral activity against both enveloped and nonenveloped viruses as compared with other antiseptic agents, such as chlorhexidine.11 PVP-I has also demonstrated in vitro activity against SARS-CoV and MERS-CoV.6
References
Dr KK Aggarwal
President CMAAO, HCFI and Past National President IMA
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}